glp-1 and fibromyalgia The Potential Indirect Impact of Receptor Agonists in the Management of Fibromyalgia[v1] Fibromyalgia and Semaglutide: Patient Outcomes – GLP-1 actions and target organs.

If reflux or other GI effects are making treatment feel harder than expected, GLP-1 medication education can help you understand the connection between slower emptying and symptom management

Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans

This is why it is recommended that during GLP1 treatments, exercise should be employed to target specific areas

Proprietary Technology LipoCap is a proprietary liposomal encapsulation technology that protects nutrients and delivers them directly to cells - ensuring superior absorption, stability and efficacy through a specialised freeze-drying (lyophilisation) process that preserves the integrity of active ingredients